港股異動 | 榮昌生物-B(9995.HK)漲逾6% 用於治療胃癌的維迪西妥單抗獲批
格隆匯6月9日丨榮昌生物-B(9995.HK)漲逾6%,報118.7港元,創逾三個月新高,最新總市值581億港元。國家藥監局發佈公吿稱,附條件批准榮昌生物自研注射用維迪西妥單抗(商品名:愛地希)上市,適用於至少接受過2種系統化療的HER2過表達局部晚期或轉移性胃癌(包括胃食管結合部腺癌)患者的治療。這是繼羅氏的Kadcyla、Seagen/武田的Adcetris之後,國內第三個獲批的ADC抗體,也是首款由本土製藥企業自主研發的ADC產品,為局部晚期或轉移性胃癌患者提供了新的治療選擇。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.